Reperfusion therapy is used to restore blood flow in blocked arteries after a heart attack. Reperfusion injury usually occurs as a result of organ transplantation and other injuries. Patients are treated with antiplatelet therapy, open or endovascular revascularization, coronary angioplasty, and others. Reperfusion injury can occur in organs such as the heart, kidneys, liver, intestines, lungs, and brain. Clinical trials are being conducted with drugs designed to treat reflux injuries. Damage to the tissue as a result of a lack of blood supply leads to reperfusion injuries. Brain damage following a stroke is one example of a reperfusion injuries. Reperfusion therapy causes blood to flow into the tissue thatcauses inflammation and oxidative damage from oxidative stress. Therapeutic hypothermia, hydrogen sulfide therapy, cyclosporins, stem cell therapy, and other methods can all be used to treat reperfusion injury. Oxidative damage happens when reperfusion therapy is delayed.
Market Dynamics
Increasing launches of new products and mergers and acquisitions by key market players are expected to drive the global reperfusion treatment market growth. For instance, on October 15, 2021, Study.com, the extensive platform for education gainers, published an article explaining the process of delivering oxygenated blood to the body's tissues known as perfusion. Physicians must first define a few terms related to the heart beat cycle in order to comprehend when perfusion occurs. Two cycles make up one heartbeat. The first cycle, referred to as the "lub," or systole, occurs when the chambers constrict and drive blood into the arteries. The second cycle, also known as the "dub" or diastole, is when the chambers relax and blood fills them.
Key features of the study:
- This report provides an in-depth analysis of the global reperfusion treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global reperfusion treatment market based on the following parameters–company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Corline Biomedical AB, SBI Holdings Inc., Pharming Group NV, Mallinckrodt Pharmaceuticals, MIFCOR, Inc., CFM Pharma Holding B.V, Balmes Transplantation SAS, Revive Therapeutics Ltd, Faraday Pharmaceuticals, Radikal Therapeutics Inc, Amyndas Pharmaceuticals, com, Inc, Angion Biomedica Corp, Young Therapeutics, LLC, Ischemix, Stealth Biotherapeutics Inc, and Bolder Bio Technology Inc
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global reperfusion treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global reperfusion treatment market
Detailed Segmentation:
- Global Reperfusion Treatment Market, By Treatment Type:
- Therapeutic Hypothermia
- Cyclosporin
- Stem Cell Therapy
- Hydrogen Sulphide Treatment
- Others
- Global Reperfusion Treatment Market, By Injury Type:
- Heart Injury
- Kidney Injury
- Intestine Injury
- Others
- Global Reperfusion Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Global Reperfusion Treatment Market, By Region:
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- U.K.
- Germany
- France
- Spain
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
- Company Profiles
- Corline Biomedical AB
- SBI Holdings Inc.
- Pharming Group NV
- Mallinckrodt Pharmaceuticals
- MIFCOR, Inc.
- CFM Pharma Holding B.V
- Balmes Transplantation SAS
- Revive Therapeutics Ltd
- Faraday Pharmaceuticals
- Radikal Therapeutics Inc
- Amyndas Pharmaceuticals, com, Inc.
- Angion Biomedica Corp
- Young Therapeutics, LLC
- Ischemix
- Stealth Biotherapeutics Inc
- Bolder Bio Technology Inc
